Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC

Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC

Introduction: The sequence of chemotherapy and pembrolizumab may affect antitumor immune response and efficacy of immunotherapy. Methods: This multicenter, randomized, phase 2 trial was designed to evaluate the efficacy of two sequences of chemotherapy and pembrolizumab in patients with stage 4 NSCL...

Full description

Bibliographic Details
Main Authors: Thomas A. Hensing, MD, MS, Xiaofei Wang, PhD, Thomas E. Stinchcombe, MD, Junheng Gao, MS, Michael V. Knopp, MD, PhD, Mark Watson, MD, PhD, Arkadiusz Z. Dudek, MD, PhD, Stephen L. Graziano, MD, Jyoti D. Patel, MD, Bryan A. Faller, MD, Konstantin H. Dragnev, MD, David Kozono, MD, PhD, Everett E. Vokes, MD
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:JTO Clinical and Research Reports
Subjects:
Clinical trial
Immunotherapy
Metastatic non–small cell lung cancer
Immunotherapy and chemotherapy sequencing
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000679

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000679

Similar Items